Oncolytics Biotech Files May 2025 Financial Report

Ticker: ONCY · Form: 6-K · Filed: May 14, 2025 · CIK: 1129928

Sentiment: neutral

Topics: financial-results, reporting, foreign-private-issuer

Related Tickers: ONCO

TL;DR

ONCOLYTICS BIOTECH (ONCO) dropped a May 2025 6-K. Check financials.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on May 14, 2025, reporting its financial results for the month of May 2025. The company is a foreign private issuer based in Calgary, Alberta, Canada, and is subject to the 1934 Securities Exchange Act. This filing is made pursuant to Rule 13a-16 or 15d-16.

Why It Matters

This filing provides investors with an update on Oncolytics Biotech's financial performance and operational status for the specified period, which is crucial for investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing (6-K) and does not contain new material events or significant financial changes.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The Form 6-K is filed by Oncolytics Biotech Inc. to report its financial results for the month of May 2025, as required by the Securities and Exchange Commission.

What is the company's SEC file number?

The SEC file number for Oncolytics Biotech Inc. is 001-38512.

Where are Oncolytics Biotech Inc.'s principal executive offices located?

The principal executive offices of Oncolytics Biotech Inc. are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.

Is Oncolytics Biotech Inc. filing an annual report under Form 20-F or 40-F?

Oncolytics Biotech Inc. indicates it files annual reports under Form 20-F.

What is the filing date of this Form 6-K?

This Form 6-K was filed on May 14, 2025.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 14, 2025 regarding ONCOLYTICS BIOTECH INC (ONCY).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing